Zealand Pharma AS (FRA:22Z)
€ 96.55 -0.4 (-0.41%) Market Cap: 6.89 Bil Enterprise Value: 5.80 Bil PE Ratio: 0 PB Ratio: 5.81 GF Score: 67/100

Zealand Pharma A/S at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 10, 2021 / 02:15PM GMT
Release Date Price: €26.78 (+0.37%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Good morning, and welcome to the second day of the 19th Annual Morgan Stanley Healthcare Conference. Before I get going, let me just read the requisite disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

And with that, I'm one of the biotech analysts here. My name is David Lebowitz. I'm happy to have with me from Zealand Pharma, CEO, Emmanuel Dulac; and CFO, Matt Dallas. I guess before we get into it, could you offer an overview of the company and tell us about what the company's overall mission is?

Emmanuel Dulac;S;CEO;President
Zealand Pharma A

/-&

Yes. Thank you, David. So Zealand Pharma is actually a 22-year-old company formed on the foundation of advancing peptides. So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot